MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

Search

Quidel Corp

Atidarymo kaina

27.06 -2.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.81

Max

27.91

Pagrindiniai rodikliai

By Trading Economics

Darbuotojai

6,600

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+1.46% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

19M

1.6B

Ankstesnė atidarymo kaina

29.09

Ankstesnė uždarymo kaina

27.06

Quidel Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-27 23:07; UTC

Uždarbis

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

2026-01-27 21:27; UTC

Uždarbis

Texas Instruments 4Q Sales Rise, Profit Falls

2026-01-27 23:55; UTC

Rinkos pokalbiai

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

2026-01-27 23:39; UTC

Rinkos pokalbiai

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Asset-Impairment Losses Weighed on Earnings

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

2026-01-27 23:19; UTC

Uždarbis

SK Innovation Posts Net Loss for Second Consecutive Year

2026-01-27 23:19; UTC

Uždarbis

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

2026-01-27 23:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-27 23:11; UTC

Rinkos pokalbiai

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

2026-01-27 23:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

2026-01-27 22:17; UTC

Rinkos pokalbiai

U.S. Dollar Slips Following Trump Comments -- Market Talk

2026-01-27 22:06; UTC

Uždarbis

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

2026-01-27 21:51; UTC

Uždarbis

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

2026-01-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-27 21:43; UTC

Uždarbis

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

2026-01-27 21:41; UTC

Uždarbis

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

2026-01-27 21:38; UTC

Uždarbis

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

2026-01-27 21:32; UTC

Uždarbis

Ampol: Modest Profit From F&I International in 2025

2026-01-27 21:32; UTC

Uždarbis

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

2026-01-27 21:31; UTC

Uždarbis

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

2026-01-27 21:31; UTC

Uždarbis

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

2026-01-27 21:30; UTC

Uždarbis

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

2026-01-27 21:28; UTC

Uždarbis

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Akcijų palyginimas

Kainos pokytis

Quidel Corp Prognozė

Kainos tikslas

By TipRanks

1.46% į viršų

12 mėnesių prognozė

Vidutinis 28.5 USD  1.46%

Aukščiausias 35 USD

Žemiausias 22 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

5 ratings

1

Pirkti

3

Laikyti

1

Parduoti

Finansinės naujienos

$

Apie bendrovę Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat